CLINICAL TRIALS PROFILE FOR DESFERAL
✉ Email this page to a colleague
All Clinical Trials for DESFERAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004982 ↗ | Combination Iron Chelation Therapy | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 | 1998-12-01 | Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial. |
| NCT00110266 ↗ | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients | Completed | Novartis Pharmaceuticals | Phase 2 | 2005-07-25 | The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions. |
| NCT00293098 ↗ | Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease | Approved for marketing | ApoPharma | 2006-03-01 | Patients who have iron overload due to chronic blood transfusions and have developed heart failure or who are at high risk of heart failure because of the high levels of iron in their hearts, will be treated with deferiprone, an investigational drug, in combination with deferoxamine (Desferal). Some studies suggest that deferiprone may be better than deferoxamine in removing iron from the heart and improving heart function, and that using both drugs together may remove more iron. Participants would make a clinic visit for lab studies each week, and would continue to take deferiprone for as long as their physician feels it is useful in their care. | |
| NCT00293098 ↗ | Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease | Approved for marketing | Children's Hospital of Philadelphia | 2006-03-01 | Patients who have iron overload due to chronic blood transfusions and have developed heart failure or who are at high risk of heart failure because of the high levels of iron in their hearts, will be treated with deferiprone, an investigational drug, in combination with deferoxamine (Desferal). Some studies suggest that deferiprone may be better than deferoxamine in removing iron from the heart and improving heart function, and that using both drugs together may remove more iron. Participants would make a clinic visit for lab studies each week, and would continue to take deferiprone for as long as their physician feels it is useful in their care. | |
| NCT00349453 ↗ | Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients | Completed | Lipomed | Phase 2 | 2005-03-01 | Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DESFERAL
Condition Name
Clinical Trial Locations for DESFERAL
Trials by Country
Clinical Trial Progress for DESFERAL
Clinical Trial Phase
Clinical Trial Sponsors for DESFERAL
Sponsor Name
